End points and safety assessments
The predefined primary end point was
absolute change in HbA1c from baseline
to week 52. Key secondary end points
were 1) absolute change in total body
weight (TBW) from baseline to week 52;
2) proportion of patients reporting at least
one episode of hypoglycemia (“major,”
“minor,” or “other,” episode) during the
52-week double-blind treatment period;
and 3) the proportion of patients achieving a
TBW decrease $5% from baseline to week
52. Major hypoglycemia was defined as a
symptomatic episode requiring external assistance
due to severely impaired consciousness
or behavior, with capillary or plasma
glucose levels of 54 mg/dL (,3.0 mmol/L)
and recovery after glucose or glucagon
administration. Minor hypoglycemia was
defined as a symptomatic episode with capillary
or plasma glucose levels of 63 mg/dL
(,3.5 mmol/L), irrespective of the need for
external assistance, or an asymptomatic
episode with capillary or plasma glucose
levels of 63 mg/dL (,3.5 mmol/L) that did
not qualify as a major episode. Other
hypoglycemia was defined as an episode
with symptoms suggestive of hypoglycemia
but without measurement confirmation.